Focused On-demand Library for Kinesin-like protein KIF20B

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q96Q89

UPID:

KI20B_HUMAN

Alternative names:

Cancer/testis antigen 90; Kinesin family member 20B; Kinesin-related motor interacting with PIN1; M-phase phosphoprotein 1

Alternative UPACC:

Q96Q89; A8MXM7; O43277; Q09471; Q2KQ73; Q32NE1; Q561V3; Q58EX8; Q5T9M8; Q5T9M9; Q5T9N0; Q5T9N1; Q7KZ68; Q7Z5E0; Q7Z5E1; Q7Z6M9; Q86X82; Q9H3R8; Q9H6Q9; Q9H755; Q9NTC1; Q9UFR5

Background:

Kinesin-like protein KIF20B, also known as Cancer/testis antigen 90 and M-phase phosphoprotein 1, plays a pivotal role in cell division by mediating cytokinesis. It is essential for midbody organization and abscission in polarized cortical stem cells. Furthermore, KIF20B is involved in neuronal polarization, facilitating the transport of specific cargos for the development of the cerebral cortex. Its function extends to promoting the transition from multipolar to bipolar stages and radial migration of cortical neurons, highlighting its significance in brain development.

Therapeutic significance:

Given its role in cell division and neuronal development, KIF20B's involvement in bladder cancer proliferation and progression underscores its potential as a therapeutic target. Understanding the role of Kinesin-like protein KIF20B could open doors to potential therapeutic strategies, especially in oncology, by targeting its function to inhibit cancer cell proliferation and promote apoptosis.